Despite global trade headwinds and a choppy market for biopharma stocks in China, WuXi AppTec Co. Ltd. (Shanghai:603259; HKSE:2359) managed to price its Hong Kong listing within its proposed range Friday, potentially raising HK$7.9 billion ($1 billion) based on its proposed number of shares.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,